Pharmaceutical Research Associates, Inc.,
Salt Lake City, Utah, 84124, United States
NCT Number: NCT04871724
A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Salt Lake City, Utah, 84124, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will receive EDP-938 once daily on Days 1 and 14
Subjects will receive fluconazole once daily on Days 5 to 18
Time frame: Up to 19 days
Time frame: Up to 19 days
Time frame: Up to 25 Days
Enanta Pharmaceuticals, Inc
Industry
A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04520659
Infections, Mononegavirales Infections
Baltimore, Maryland, United States
View Trial DetailsNCT05765396
COVID-19, COVID-19 Pneumonia
Fort Sam Houston, Texas, United States
View Trial DetailsNCT05268939
COVID-19, Coronaviridae Infections
Cullman, Alabama, United States
View Trial DetailsNCT04782336
COVID-19, Coronaviridae Infections
Cambridge, United Kingdom
View Trial Details